NCT04248543View on ClinicalTrials.gov

Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions
Spinal Metastases
Interventions
DEVICE

qMRI with Gadoteridol contrast agent

quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.

Trial Locations (1)

27710

Duke Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT04248543 - Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases | Biotech Hunter | Biotech Hunter